Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Down 23.1% in February

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 386,035 shares, a decline of 23.1% from the January 29th total of 502,013 shares. Currently, 11.2% of the shares of the company are short sold. Based on an average daily volume of 357,684 shares, the short-interest ratio is presently 1.1 days. Based on an average daily volume of 357,684 shares, the short-interest ratio is presently 1.1 days. Currently, 11.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several research firms have commented on JAGX. Wall Street Zen lowered shares of Jaguar Animal Health to a “strong sell” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $60.00.

Jaguar Animal Health Price Performance

JAGX stock traded down $0.19 during midday trading on Tuesday, reaching $0.62. 1,380,627 shares of the stock were exchanged, compared to its average volume of 5,506,251. Jaguar Animal Health has a 52 week low of $0.56 and a 52 week high of $15.48. The company has a fifty day moving average price of $0.83 and a 200 day moving average price of $1.43. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52. The stock has a market capitalization of $2.30 million, a PE ratio of -0.02 and a beta of 0.02.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.